02 February 2026
02 February 2026
The Mosaic 3D device incorporates several features designed to enhance safety and patient comfort.
The programme will focus on accelerating treatments for rare diseases, most of which currently lack approved therapies.
Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation submission.
Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
